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Sprespeciﬁed primary endpoint is the comparison of "NACCE" or net adverse cardiac
and cerebrovascular events (death, myocardial infarction, cerebrovascular accident,
and major bleeding) at 12 months after implantation. After performing propensity
scoring to adjust for differences in baseline characteristics, the noninferiority of the 3-
month DAPT arm to the 12-month DAPT arm will be assessed with respect to the
incidence of NACCE.
Results: There were 1,205 patients enrolled in the 3-month DAPT arm and 1,345
patients included on the 12-month DAPT arm. Baseline characteristics of both groups
were: men, 75.4% and 74.3%; mean age, 68.7 and 67.6 years; diabetes, 32.6% and
35.0%; acute coronary syndrome, 40.7% and 36.3%; number of lesions, 1,453 and
1,738; target vessel lesions,LMCA (0.3% and 0%), LAD (51.3% and 43.4%), LCX
(18.4% and 18.4%), and RCA (30.0% and 38.2%); de novo lesions, 99.3% and
97.5%; reference vessel diameter, 2.71 mm and 2.58 mm; pre-minimum lumen
diameter, 0.81 mm and 0.75 mm; pre-% diameter stenosis, 70.0% and 71.0%; lesion
length, 15.7 mm and 16.8 mm; and total stent length, 21.4 mm and 24.4 mm.
Conclusions: Baseline characteristics of both arms were similar. The present study
will provide insight into the optimal duration of DAPT after E-ZES implantation. Per-
protocol analysis results will be presented at TCT in 2013.
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Background: Cilostazol may have a positive chronotropic or pro-arrhythmic effect,
despite its beneﬁcial effects on vasodilation and antiplatelet aggregation. However, it
is unknown whether adjunctive cilostazol can contribute to tachycardia or arrhythmias
after drug-eluting stents (DES) implantation. The aim of this study was to determine
the impacts of adjunctive cilostazol on 24-hour heart rate and arrhythmias in patients
undergoing DES implantation.
Methods: This randomized, multicenter, prospective trial compared triple antiplatelet
therapy (aspirin, clopidogrel, and cilostazol, TAT, n ¼ 113) and dual antiplatelet
therapy (aspirin and clopidogrel, DAT, n ¼ 114) at baseline and 6-month in patients
receiving DES. The primary end points were 24-hour heart rate (24h-HR), 24h-HR
70 bpm, and 24h-HR increase 5 bpm at 6-month follow-up using 24-hour Holter
electrocardiographic monitoring. Secondary end points were counts or presences of
premature ventricular complex (PVC), nonsustained ventricular tachycardia, sustained
ventricular tachycardia, premature atrial complex, and supraventricular tachycardia at
6-month.
Results: The two groups had similar baseline characteristics. At 6-month follow-up,
the 24h-HR (75.4  11.7 bpm vs. 69.3  10.0, p < 0.001), presence of 24h-HR 70
bpm (71.4% vs. 47.1%, p < 0.001), and presence of 24h-HR increase 5 bpm (44.8%
vs. 24.5%, p ¼ 0.002) were signiﬁcantly higher in the TAT versus DAT group.
Multivariate analysis showed that the use of cilostazol (OR: 3.10, 95% CI: 1.08 to
8.89) and baseline 24-HR < 70 bpm (OR: 4.60, 95% CI: 1.16-13.14) were strong
predictors of 24h-HR increase 5 bpm at follow-up. In addition, 24h total counts of
PVCs (472  1497 beats vs. 86  209 beats, p ¼ 0.016) was signiﬁcantly higher in
the TAT versus DAT group among the secondary end points.
Conclusions: Cilostazol in addition to DAT appears to result in an increase in 24h-HR
and total counts of PVCs after DES implantation. Some caution should be exercised
for the use of cilostazol in patients with tachycardia or a large number of PVCs, when
planning DES implantation.
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Background: The present study aims to evaluate the impact of hemoglobin and
hematocrit (H&H) on different assay methods used to test on-treatment platelet
reactivity to clopidogrel.
Methods: Platelet reactivity was tested in 466 consecutive patients with VerifyNow
(VN) P2Y12, vasodilator-stimulated phosphoprotein phosphorylation (VASP), and
light transmission aggregometry (LTA) with adenosine diphosphate (ADP) 5- and 20-B46 JACC Vol 62/18/Suppl B j October 27–NovemmM assay 6 to 24 hours after PCI. Low hemoglobin was deﬁned as level <12 for
women and <13 for men. Patients were stratiﬁed into low and normal hemoglobin
groups.
Results: Using VN-P2Y12 assay, patients with low hemoglobin had higher, mean
PRU (211119 vs.15894, p<0.001) and higher BASE values (34154 vs. 28858,
p<0.001) compared to patients with normal hemoglobin. The reported mean percent
inhibition (4037 vs. 4631, p¼0.16) was similar between groups. No differences
were noted in mean platelet reactivity between the two groups by LTA ADP 5mM
(3818 vs. 3514, p¼0.12), ADP 20mM (4720 vs. 4417, p¼0.19) and VASP
(4127 vs.3826, p¼0.27). In a multivariate logistic regression model, baseline
hematocrit was an independent correlate for PRU208 (OR 0.91, 95% CI 0.86-0.96)
but has no impact on HTPR by LTA ADP 5 mM 46 (OR 1.0, 95% CI 0.95-1.05),
LTA ADP 20 mM 59 [OR 1.01, 95% CI 0.96-1.06) or VASP PRI50% [OR 1.0,
95% CI 0.95-1.05).Conclusions: The results show that the on-treatment platelet reactivity to clopidogrel
measured by VerifyNow P2Y12 PRU is signiﬁcantly inﬂuenced by patient's baseline
H&H, while the platelet reactivity measured by LTA and VASP does not seem to be
impacted.
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Background: It has been well known that the inhibition of platelet aggregation (IPA)
by anti-platelet agents was important to reduce the thrombo-embolic events in patients
with ST segment elevation myocardial infarction (STEMI). However, the peri-
procedural IPA by anti-platelet agents was not well known.
Methods: We compared the peri-procedural IPA between prasugrel and adjunctive
cilostazol to dual anti-platelet therapy (Triple anti-platelet therapy; TAP) in patients
with STEMI undergoing primary percutaneous coronary intervention (PCI). We
prospectively randomized 70 consecutive clopidogrel-naive patients with STEMI
planned PCI to either prasugrel [loading dose (LD) 60 mg; 37 patients] or TAP (LD
aspirin 300 mg, clopidogel 600 mg, and cilostazol 200 mg; 33 patients). Primary end
points of the study were the platelet reactivity unit (PRU) or % inhibition by the
VerifyNow P2Y12 assay at pre-PCI and pre-discharge.
Results: The drug loading to pre-PCI time was similar between prasugrel and TAP
groups (25.4  10.42 minutes vs. 25.5  10.56 minutes, p ¼ 0.957). PRU at pre-PCI
was signiﬁcantly lower in prasugrel than in TAP (269.1  71.69 vs. 306.5  48.67,
p ¼ 0.012). The lower PRU and greater % inhibition also observed in prasugrel than in
TAP at pre-discharge (108.2  60.51 vs. 238.1  73.40; 63.6  18.51% vs. 16.8 
17.91%, p <0.001 respectively). No differences in in-hospital bleeding complications
between two groups were observed.
Conclusions: Our study demonstrates that prasugrel could produce a signiﬁcantly
greater peri-procedural as well as in-hospital IPA compared with TAP in patients with
STEMI undergoing primary PCI.ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
